Literature DB >> 1720501

Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies.

J Wijdenes1, C Clement, B Klein, B Morel-Fourrier, N Vita, P Ferrara, A Peters.   

Abstract

Three different epitopes of the human IL-6 (IL-6) molecule were recognized by the mAb B-E4 (IgG2b), B-E8 (IgG1) and B-F6 (IgG1). The affinities of these three mAb for IL-6 differ little in several assays but if ranked by affinity they fall into the following order B-E8 greater than B-E4 greater than B-F6. B-E4 and B-E8 mAb, recognizing two different epitopes, are inhibiting mAb in the bioassay with the IL-6 depending cell line B9, however B-E8 has an inhibiting activity higher than B-E4. Both human natural IL-6 (HnIL-6) and human recombinant IL-6 (HrIL-6) were inhibited but not the murine natural IL-6 (MnIL-6). Surprisingly, not only the non-inhibiting mAb (B-F6) recognizes the HrIL-6 fixed to the receptor but also the inhibiting mAb B-E4 and B-E8. This together with the results obtained in a sandwich ELISA where the same mAb was used as both catcher and tracer to detect HrIL-6, it was concluded that dimeric HrIL-6 is able to fix the IL-6 receptor. Competition studies between monomeric HnIL-6 and dimeric HrIL-6 showed that the affinity of the dimeric HrIL-6 for the receptor was higher than that of HnIL-6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720501     DOI: 10.1016/0161-5890(91)90004-4

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.

Authors:  J-F Rossi; N Fegueux; Z Y Lu; E Legouffe; C Exbrayat; M-C Bozonnat; R Navarro; E Lopez; P Quittet; J-P Daures; V Rouillé; T Kanouni; J Widjenes; B Klein
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

Authors:  A C Sprynski; D Hose; A Kassambara; L Vincent; M Jourdan; J F Rossi; H Goldschmidt; B Klein
Journal:  Leukemia       Date:  2010-09-16       Impact factor: 11.528

3.  Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain.

Authors:  J P Gaillard; J Liautard; J C Mani; J M Fernandez Suarez; B Klein; J Brochier
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

4.  Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia.

Authors:  R Bataille; X G Zhang; J Wijdenes; J F Schved; B Klein
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

5.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

6.  The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Authors:  Anne Catherine Sprynski; Dirk Hose; Laurent Caillot; Thierry Réme; John D Shaughnessy; Bart Barlogie; Anja Seckinger; Jérôme Moreaux; Michael Hundemer; Michel Jourdan; Tobias Meissner; Anna Jauch; Karène Mahtouk; Alboukadel Kassambara; Uta Bertsch; Jean François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2009-02-18       Impact factor: 22.113

7.  Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.

Authors:  E Legouffe; J Liautard; J P Gaillard; J F Rossi; J Wijdenes; R Bataille; B Klein; J Brochier
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

8.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

9.  Interferon gamma inhibits interleukin 10 production by monocytes.

Authors:  P Chomarat; M C Rissoan; J Banchereau; P Miossec
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

Review 10.  Post-stroke inflammation-target or tool for therapy?

Authors:  Kate Lykke Lambertsen; Bente Finsen; Bettina Hjelm Clausen
Journal:  Acta Neuropathol       Date:  2018-11-27       Impact factor: 17.088

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.